

CURRICULUM VITAE
Phu V. Truong, M.D., FACP

Education	University of Kansas School of Medicine – Wichita Clinical Assistant Professor	2006-Present
	Fred Hutchinson Cancer Research Center Hematopoietic Stem Cell Transplantation Visiting Fellowship	2005
	University of Texas Southwestern Medical Center Hematology/Oncology Fellowship	2002-2005
	University of Kansas School of Medicine-Wichita Internal Medicine Residency	1999-2002
	University of Kansas School of Medicine Doctor of Medicine	1995-1999
	University of Kansas Bachelor of Science Cellular Biology (Highest Distinction)	1991-1995
Certification	The American Board of Internal Medicine: Medical Oncology	2005-Present
	Hematology	2005-Present
	Internal Medicine	2002-Present
Licensure	Texas State Board of Medical Examiners	2002-2005
	Kansas State Board of Healing Arts	2000-Present
Honors & Awards	Silver Award (15-19 Total Accruals in WCCOP NCI Treatment and Cancer Control Clinical Trials)	2011
	R.M. Gouldner Medical Scholarship	1998
	Arthur Miller Medical Scholarship	1998
	Dean’s List KU School of Medicine	1995-1999
	Summerfield Scholar	1991-1995
	O. Maloney Scholarship for Excellence in Chemistry	1992
	State of Kansas Science Olympiad Champions	1990 & 1991
Research Experience	Investigator, Cancer Research Center of Kansas (CRCK)	2019-Present
	Investigator, Wichita NCI Community Oncology Research Program (NCORP)	2005-2019
	Women’s Research Institute, Brooks Keel, Ph.D. “Effect of Alphafetoprotein on Cell Proliferation & Differentiation”	1991

Presentations

1. Truong PV, Saltzman M, Bessudo A, Jawien W, Lyons RM, Berenzon D, Mena R, Wingate-Pearse N, Barriere O, Beeson HE, Glidde PF, Choy GS, Verstovsek S: Final Results of Anagrelide Controlled-Release (GALE-401) Safety, Efficacy and Pharmacokinetics in Subjects with Myeloproliferative Neoplasms (MPN)-Related Thrombocytosis. Poster abstract presented at 57th Annual ASH Conference, December 7, 2015.

Publications (including Abstracts)

1. Esber N, Howle K, Orozco-Do S, Truong P, Grant ME, Shaver T: Systemic Lupus Erythematosus, Immune Thrombocytopenic Purpura, and Autoimmune Hemolytic Anemia. *Ks J Medicine.* 2009 (case report)
2. Rahal AK, Truong PV, Kallail KJ: Oxaliplatin-Induced Tonic-Clonic Seizures. *Case Rep Oncol Med.* 2015;2015:879217. Epub 2015 Sep 30.
3. Byrd K, Trong PV: Bortezomib in the Treatment of Acquired Von Willebrand Disease Secondary to Monoclonal Gammopathy of Undetermined Significance *Kansas Journal of Medicine.* 2014, November; 7(4):167-170.
4. Truong P, Rahal A, Kallail K (June 4, 2016): Metastatic Hepatocellular Carcinoma Responsive to Pembrolizumab. *Cureus.* 8(6): e631.
5. Chambers I, Truong P, Kallail K, et al (June 13, 2016): Extensive Bone Marrow Necrosis and Osteolytic Lesions in a Case of Acute Myeloid Leukemia Transformed from Polycythemia Vera. *Cureus* 8(6): e639.
6. Reddy PS, Rahal AK, Kallail KJ, Moore DF, Truong PV, Mattar BI, Cannon MW, Nabbout NH, Page SJ, Truong QV, Dakhil C, Deutsch JM, Dakhil SR: The Application of Next-Generation Sequencing in the Community Clinical Oncology Setting. *J Clin Oncol.* 34, 2016 (suppl; abstr e23145).
7. Young, Derek, et al. "A Retrospective Analysis Comparing Efficacy of Filgastrim-sndz Versus Filgastrim for Autologous, Peripheral Stem Cell Mobilization in Patients With Multiple Myeloma and Lymphoma." *ASCO Annual Mtg.* 1-5 May 2018
8. Truong, P. V., Saltzman, M., Bessudo, A., Jawien, W., Lyons, R. M., Berenzon, D., Mena, R., Wingate-Pearse, N., Barriere, O., Beeson, H. E., Glidden, P. F., Choy, G. S., & Verstovsek, S. (2015). Final Results of Anagrelide Controlled-Release (GALE-401) Safety, Efficacy and Pharmacokinetics in Subjects with Myeloproliferative Neoplasms (MPN)-Related Thrombocytosis. *Blood,* 126(23),4074. *American Society of Hematology.* 3 December 2015.
9. Rizvi, Wajeeha et al. Metastatic Breast Cancer with BRCA Mutation Discovered By Next-Generation Sequencing Responding to Olaparib. *Cureus* vol. 9,6 e1337. 11 Jun. 2017, doi:10.7759/cureus.1337
10. Tarhini AA, Lee SJ, Li X, et al. E3611-A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon- α 2b in Advanced Melanoma. *Clin Cancer Res.* 2019;25(2):524–532. doi:10.1158/1078-0432.CCR-18-2258
11. Al Attar L, Truong P. The Effect of Pembrolizumab in Absence of Programmed Death 1 Receptor. *Cureus.* 2018;10(6):e2896. Published 2018 Jun 29. doi:10.7759/cureus.2896

12. Choucair K, Parker NA, Al-Obaidi A, Alderson J, Truong P. Solitary, Late Metastatic Recurrence of Renal Cell Carcinoma to the Pancreas: A Case Report. *Cureus*. 2020;12(6):e8521. Published 2020 Jun 9. doi:10.7759/cureus.8521
13. Parker N., Al-Obaidi A., et al. Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type: A Narrative Review. *Science Repository*. 2020. Published 2020 Jul 20. DOI: 10.31487/j.COR.2020.07.07
14. Al-Obaidi A, Parker N A, Choucair K, et al. (June 16, 2020) Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type: A Case Report. *Cureus* 12(6): e8651. doi:10.7759/cureus.8651

Poster Sessions

1. "A Randomized Phase II Study of Ipilimumab at 3 (ipi3) or 10 mg/kg (ipi10) Alone or in Combination with High Dose Interferon-Alfa (HDI) in Advanced Melanoma (E36110)." Presented at 2017 ASCO Annual Meeting.

Professional Memberships

	Fellow of the American College of Physicians (FACP)	
American Society for Blood and Marrow Transplantation		2005
American Society of Clinical Oncology		2003
American Society of Hematology		2003
American College of Physicians		1998
American Medical Association		1995

Employment Experience

Cancer Center of Kansas P.A.		11/01/2005 to Present
3243 E. Murdock, Suite 300 Wichita, KS 67208		
Veteran's Affairs North Texas Healthcare System		2002-2005
Emergency Services of Kansas, P.A.		2001-2002
Wichita Clinic, P.A.		2000-2002

Hospital Appointments

Via Christi Regional Medical Center, Wichita, KS		
Wesley Medical Center, Wichita, KS		
Wesley Oncology Medical Director		2015-Present

Languages

English
Vietnamese

Updated: 07/23/2020